15 results about "Vascular embolization" patented technology

The present invention relates to a temperature-responsive in situ gelling composition comprising an amphiphilic triblock copolymer of polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-PPO-PEO), a water-soluble hydrophilic polymer, wherein the composition further comprises at least one lipid agent. The lipid agent is selected from the group consisting of a phospholipid, a sterol, a glyceride, a fatty acid or ester and derivative, a fatty alcohol, a cholesterol and derivative or a combination of more than one lipid agent. The present invention further relates to a vascular embolization agent comprising the temperature-responsive in situ gelling composition.

The invention provides an injection hydrogel for vascular embolism treatment and a preparation and formula optimization method thereof. The hydrogel formula comprises two or more 2-arm or multi-arm polyethylene glycol polymers containing functional groups which can be cross-linked with each other, lithium magnesium silicate and a contrast agent. The formula optimization method comprises the following steps: designing an orthogonal experiment, systematically investigating the influence of raw material factors (such as polyethylene glycol molecular weight, functional groups, concentration and the like) on product performances of shear viscosity eta, compression strength sigma c and tensile strength sigma t, and obtaining basic experiment data; establishing a chemical reaction kinetic model and a product performance prediction model based on machine learning based on the data; determining a multi-objective optimization objective function according to product performance requirements; establishing a non-linear multi-objective equation set for formula optimization in combination with a material proportioning relationship; solving the optimization model by adopting an intelligent optimization algorithm to obtain a preliminary optimization formula; carrying out an optimization experiment under a small-scale test condition to obtain new experiment data, and updating model parameters; and the optimization iteration is repeated until convergence.

The invention discloses a locally degradable vascular embolism spring ring. The spring ring comprises an inner core shaft; the degradable spring is sleeved on the inner core shaft; the macromolecular binding wire harness is used for binding and fixing the inner core shaft and the degradable spring; wherein a plurality of binding position points are arranged on the spring rings, the macromolecule binding wire harnesses are arranged at the binding position points, the macromolecule binding wire harnesses are wound on the spring rings by at least one circle to form binding winding lantern rings, and the wire harnesses of the binding winding lantern rings are locally embedded into gaps between the degradable spring rings. And the wire harness embedded in the gap between the degradable spring rings is also partially wound on the inner core shaft. The invention further discloses a manufacturing method of the locally degradable vascular embolism spring ring. Compared with the prior art, the problem that the inner core shaft and the outer-layer degradable spring displace and slide beyond the allowable range in the pushing process when the spring ring is placed into a blood vessel is solved.

The utility model relates to the technical field of medical instruments, in particular to a vascular embolism stripping and suction catheter system. The vascular embolism stripping and suction catheter system comprises a catheter, a compressible and self-expanding thrombus cutting stripper and a traction silk thread, a traction cavity and a negative pressure cavity are formed in the catheter in the length direction of the catheter, the traction silk thread penetrates through the traction cavity, one end of the traction silk thread is connected with the thrombus cutting stripper, and the other end of the traction silk thread is connected with the negative pressure cavity. One end of the negative pressure cavity is communicated with the catheter, the other end of the negative pressure cavity penetrates out of the other end of the catheter, the thrombus cutting detacher can be compressed to be arranged in the traction cavity or can be released outside the catheter in a self-expanding mode, and the other end of the catheter is provided with a negative pressure connector communicated with the negative pressure cavity. The device has the advantages that the structural design is simple and reasonable, the wall-attached embolism can be effectively cut and crushed and then sucked out through negative pressure, and the embolism can be taken out more easily.

This vascular embolization agent contains solid particles of two or more amino acids having different solubilities as an active ingredient. The solid particles dissolve in physiological saline at 37°C within 6 hours. This production method for a vascular embolization agent includes a step for adjusting the dissolution rate of solid particles of two or more amino acids that have different solubilities and serve as an active ingredient so that the solid particles dissolve in physiological saline at 37°C within 6 hours.

This invention belongs to the field of vascular embolization treatment device technology, and discloses a robot for vascular embolization, comprising magnetic particles and an elastic polymer substrate, wherein the magnetic particles are dispersed in the elastic polymer substrate; the robot's initial shape is a helical hollow structure, and the elastic polymer substrate is fibrous and distributed in a spiral shape; the robot can deform under the action of an external magnetic field. This invention improves the structure and composition of the robot, utilizing magnetic particles in conjunction with the elastic polymer substrate to form a spiral-shaped fiber, resulting in a magnetic robot with high maneuverability and shape reconfigurability. In particular, it can perform robotic embolization in the sub-millimeter region remotely, without restraint, and in a magnetically controllable manner. Compared with existing robots, the robot of this invention is compatible with current clinical catheters, has high flexibility in intravascular movement, good maneuverability, and can fulfill the needs of multifunctional embolization.

The invention relates to the technical field of embolism materials, in particular to a blood vessel embolism composition containing a biocompatible polymer and a preparation method of the blood vessel embolism composition, and the blood vessel embolism composition comprises the biocompatible polymer and a biocompatible iodine-containing developer; the biocompatible polymer is selected from a polylactic acid-glycolic acid copolymer (PLGA), polycaprolactone (PCL), a polyethylene glycol-polylactic acid copolymer (PEG-PLA) or poly trimethylene carbonate (PTMC); the biocompatible iodine-containing developing agent is selected from a triiodo phenoxyethyl acrylate-hydroxyethyl methylacrylate copolymer, iohexol, triiodo phenol, iopromide or iopamidol; a biocompatible iodine-containing developing agent is adopted, so that metal toxicity is avoided, the developing strength is high and uniform, and clinical precise positioning is met; the compatibility and the dispersity are good.

This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.

The present application relates to the technical field of embolic material, in particular to a vascular embolization composition containing a biocompatible polymer and a preparation method thereof, comprising a biocompatible polymer and a biocompatible iodine-containing contrast agent; the biocompatible polymer is selected from polylactic acid-glycolic acid copolymer PLGA, polycaprolactone PCL, polyethylene glycol-polylactic acid copolymer PEG-PLA or polytrimethylene carbonate PTMC; the biocompatible iodine-containing contrast agent is selected from triiodophenoxy ethyl acrylate-hydroxyethyl methacrylate copolymer, iohexol, triiodophenol, iopromide or iopamidol; the biocompatible iodine-containing contrast agent is used to avoid metal toxicity, has high and uniform development intensity, meets clinical precise positioning, and has good compatibility and dispersibility.

This invention discloses the preparation and application of radiofrequency thermoresponsive platinum ion crosslinked black phosphorus nanogel. The nanogel has a core-shell structure, comprising a core composed of a radiofrequency thermosensitive agent and chemotherapeutic drugs, and a shell constructed from a thermosensitive nanopolymer. The thermosensitive nanogel BP-Pt@PNA prepared using the above components exhibits radiofrequency thermosensitive properties. Simultaneously, the introduction of the thermosensitive nanopolymer improves the stability of the radiofrequency thermosensitive agent and chemotherapeutic drugs, enabling long-term drug retention and fully leveraging the synergistic effect of non-invasive radiofrequency thermotherapy and chemotherapy. This drug-loaded nanogel can achieve multimodal treatment applications, including non-invasive radiofrequency thermotherapy-chemotherapy synergistic antitumor therapy and invasive radiofrequency ablation-chemotherapy-vascular embolization synergistic antitumor therapy, demonstrating significant clinical translational potential.

This invention provides a vascular embolization treatment device, relating to the field of vascular embolization medical device technology. It includes a delivery tube and a spring coil. The spring coil includes a spring coil body and an end fixed to the distal end of the spring coil body. It also includes an end control mechanism and a spring coil control mechanism, with the distal end of the end control mechanism detachably connected to the proximal end of the end. The distal end of the delivery tube is detachably connected to the proximal end of the spring coil body via the spring coil control mechanism. This invention can improve the success rate of spring coil formation, avoid mis-embolization, and reduce surgical risks.

The invention discloses a high-strength crosslinked chitosan derivative as well as a preparation method and application thereof, and relates to the technical field of medical polymer materials. The product provided by the invention is prepared by a two-step modification process of first crosslinking and then etherification. The product is prepared by taking recrystallized chitosan as a base material, selecting ethylene glycol diglycidyl ether, lactic acid or citric acid as a cross-linking agent for pre-crosslinking to construct a network skeleton, and introducing a hydrophobic chain segment through ring opening etherification of 1, 2-epoxybutane. By optimizing the raw material ratio and reaction conditions, the prepared chitosan derivative has excellent mechanical strength and temperature-sensitive responsiveness, has good fluidity at low temperature, is convenient to smear, and can be quickly gelatinized to form a stable adhesion layer after contacting with body temperature. The product is high in purity and good in biocompatibility, and can be widely applied to the fields of wound dressings, vascular embolism, skin filling and repairing, drug-loaded slow release and the like.

The application relates to a deep learning-based vascular embolism identification method, which comprises the following steps: obtaining seed points of a to-be-identified abdominal medical image according to an abdominal aorta blood vessel image and a trained first model; performing semi-automatic segmentation on a mesenteric artery region in the image by using a GrowCut algorithm on the seed points; extracting the image of the mesenteric artery region; inputting the image of the mesenteric artery region into a VTK platform; demarcating an arterial blood vessel center line of the image of the mesenteric artery region; inputting the image of the mesenteric artery region with the demarcated arterial blood vessel center line into a second model; and determining whether a thrombus exists in the to-be-identified abdominal medical image and the position of the thrombus. The application can more comprehensively capture influencing factors of acute superior mesenteric artery thrombosis, screen out relevant strong predictors, accurately identify the superior mesenteric artery thrombosis on a CT image, and enhance the prediction ability of the model. The application also relates to an equipment and a storage medium.

The application is a kind of device for evaluating the degree of vascular intervention embolization based on local arterial pressure, which comprises a module for evaluating the degree of vascular intervention embolization; the module for evaluating the degree of vascular intervention embolization calculates the degree of vascular intervention embolization according to the following formula: wherein t is a time coefficient, which is 0 when the embolic agent starts to be injected, and F (t) is the degree of vascular embolization characterized based on local arterial pressure, which changes with the injection of embolic agent; P 1(t＝0) P is the initial vascular pressure collected at G point of the blood vessel before drug injection, Fin P is the final vascular pressure collected when the simulation intervention embolization operation reaches the embolization end point; P * 1 is the converted vascular pressure of G point. The application realizes the evaluation of the embolization end point in the vascular intervention embolization operation, can more objectively and accurately evaluate whether the embolization end point is reached, and can effectively reduce the radiation damage to patients and medical staff.

The application discloses a peripheral vascular embolization efficiency evaluation method, and comprises the following steps: ear general appearance, ear angiography, pathological staining, and rabbit ear artery embolization efficiency score. The application further discloses a peripheral vascular embolization efficiency evaluation system. The application discloses a quantitative index for judging embolization efficiency, and comprehensively evaluates the embolization effect from macro to micro through three dimensions, three levels, from general appearance to angiography to pathological evaluation, so that the evaluation standard is more perfect.